Portfolio company
Aravax
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This clinical-stage pharmaceutical company develops peptide immunotherapies for patients with food allergies, including a lead product for peanut allergy.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Alladapt Immunotherapeutics
This biopharmaceutical company develops oral immunotherapies for patients with single or multiple food allergies to reduce the severity of allergic reactions.
Tolergyx
This company develops gastrointestinal immunotherapy capsules to treat food allergies in pediatric and adult patients.
Moonlight Therapeutics
This biotechnology company develops microneedle dermal stamps that deliver allergen immunotherapy to patients suffering from peanut and other food allergies.
ARS Pharmaceuticals
ARS Pharmaceuticals develops a needle-free nasal spray for patients and caregivers to treat severe allergic reactions, including anaphylaxis.
Desentum
This biopharmaceutical company develops allergen immunotherapy products to treat patients suffering from respiratory and food allergies.
ANERGIS SA
Anergis SA develops ultra-fast synthetic vaccines to treat patients suffering from frequent environmental allergies such as birch pollen and house dust mites.
Apitope
Apitope develops antigen-specific peptide therapeutics to treat autoimmune diseases and allergies for patients requiring targeted immunotherapy and immune tolerance restoration.
Poplar Therapeutics
The company develops anti-immunoglobulin E antibody therapies to treat patients with food allergies and other atopic conditions.
